share_log

CRISPR Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

CRISPR Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

CRISPR Therapeutics | S-8：员工福利计划证券登记
美股sec公告 ·  08/05 16:57
Moomoo AI 已提取核心信息
CRISPR Therapeutics AG, a biotechnology company, has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission on August 5, 2024. The filing is for the purpose of registering an additional 1,000,000 common shares at CHF 0.03 per share under the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan. This move is to facilitate the issuance of stock options and incentive plans to employees and directors. The registration statement incorporates by reference the contents of previous filings related to the 2018 Plan. The company, headquartered in Zug, Switzerland, with executive offices in South Boston, MA, is listed as a large accelerated filer. The filing includes various exhibits, such as the opinion of Swiss counsel regarding the validity of the common shares and the consent of Ernst & Young LLP as the independent registered public accounting firm.
CRISPR Therapeutics AG, a biotechnology company, has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission on August 5, 2024. The filing is for the purpose of registering an additional 1,000,000 common shares at CHF 0.03 per share under the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan. This move is to facilitate the issuance of stock options and incentive plans to employees and directors. The registration statement incorporates by reference the contents of previous filings related to the 2018 Plan. The company, headquartered in Zug, Switzerland, with executive offices in South Boston, MA, is listed as a large accelerated filer. The filing includes various exhibits, such as the opinion of Swiss counsel regarding the validity of the common shares and the consent of Ernst & Young LLP as the independent registered public accounting firm.
生物技术公司CRISPR Therapeutics AG于2024年8月5日向证券交易委员会提交了S-8表格的注册申请。此次申请的目的是在CRISPR Therapeutics AG 2018年期权和激励计划下以每股0.03瑞士法郎的价格注册额外的1,000,000股普通股。这一举措旨在为员工和董事发行股票期权和激励计划。该注册申报文件将之前有关2018年计划的文件内容作为参考。该公司总部位于瑞士楚格，行政办公室位于波士顿南部，列为大型加速的申报者。申请文件包括各种附件，例如瑞士法律顾问就普通股合法性的意见及作为独立注册会计师事务所的安永会计师事务所的同意书。
生物技术公司CRISPR Therapeutics AG于2024年8月5日向证券交易委员会提交了S-8表格的注册申请。此次申请的目的是在CRISPR Therapeutics AG 2018年期权和激励计划下以每股0.03瑞士法郎的价格注册额外的1,000,000股普通股。这一举措旨在为员工和董事发行股票期权和激励计划。该注册申报文件将之前有关2018年计划的文件内容作为参考。该公司总部位于瑞士楚格，行政办公室位于波士顿南部，列为大型加速的申报者。申请文件包括各种附件，例如瑞士法律顾问就普通股合法性的意见及作为独立注册会计师事务所的安永会计师事务所的同意书。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息